Biotechnology

Flex AI Launches First Commercial Real-Time Exercise Form Analysis Platform After Seven-Year Development Cycle

December 10, 2025 8:25 PM

Flex AI has officially launched what industry observers are calling the first successful implementation of real-time exercise form analysis using standard smartphone cameras, marking a significant milestone in the intersection of fitness technology and artificial intelligence. The platform, developed over seven years by CEO Amin Niri and Head of AI Amol Gharat, addresses what has been a persistent challenge in the fitness tech sector: providing...

Read more

Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies

December 10, 2025 6:00 PM

Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative cell-penetrating peptide-based uptake study (the "Study") of GLP/GIP[1]-based obesity therapies, further advancing its novel transdermal platform for obesity and metabolic disease. This initiative is intended to further the Company's research and development of patient-friendly, needle-free delivery...

Read more

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."

December 10, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." All reports on IGC...

Read more

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

December 9, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced it has reached a key enrollment milestone of 65% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease. This milestone marks a significant step in advancing IGC-AD1,...

Read more

uBriGene Biosciences and Circurna Announce Strategic Partnership to Accelerate Development and Manufacturing of Circular RNA/LNP Therapeutics

December 9, 2025 9:00 AM

uBriGene Biosciences, a global CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, today announced a strategic partnership with Circurna, a biotechnology company pioneering next-generation circular RNA (circRNA) therapeutics. The collaboration aims to integrate uBriGene's end-to-end process development, analytical, and GMP manufacturing capabilities with Circurna's proprietary circRNA platform to...

Read more

Hememics' Graphene-Based ESAP(TM) Platform Validated by KanPro Research, Securing Commercial Trial Order

December 9, 2025 8:00 AM

Hememics Biotechnologies, Inc., a pioneer in graphene-based biosensing technology, today announced the successful on-site demonstration of its ESAP™ (Electrostatic Sensing for Analyte Profiling) platform at KanPro Research, Inc., a premier protein science and biomanufacturing CRO founded by Dr. Philip Gao. Following a successful initial blind study that established proof-of-concept, and a subsequent on-site demonstration confirming the ability...

Read more

Senior Pharma and Biotech Leaders to Convene for Industry Forum at San Francisco CEO Ahead of JP Morgan Healthcare Conference

December 9, 2025 7:00 AM

Longwood Healthcare Leaders will convene top biopharmaceutical leaders at San Francisco CEO for two days of discussion, January 10-11, 2026, the weekend immediately prior to the 44th Annual JP Morgan Healthcare Conference. San Francisco CEO is held at the Four Seasons Hotel San Francisco, 757 Market Street, in downtown San Francisco, and features approximately nearly 200 speakers across government, pharma, biotech, academia, regulatory, and...

Read more

Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer

December 9, 2025 6:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for Phase 2/3 clinical trials of HLX22 (recombinant humanised anti-HER2 monoclonal antibody injection) in combination with HLX87 (an antibody-drug conjugate targeting HER2) have been approved by China's National Medical Products Administration (NMPA). The trials are intended for first-line treatment of...

Read more

Ayrmid Presents New Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease

December 8, 2025 9:00 AM

Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced encouraging new data on the use of motixafortide, a long-acting CXCR4 inhibitor licensed by Ayrmid under the brand name APHEXDA®, for mobilizing HSCs in patients with sickle cell disease undergoing gene therapy. The results were presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place from Dec 6-9 in Orlando FL. This...

Read more

Regentis Biomaterials Commences Trading on NYSE: Set to Transform Cartilage Repair Market with Off-the-Shelf Regenerative Product

December 8, 2025 8:33 AM

Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a late clinical stage regenerative medicine company focused on innovative tissue repair solutions, is now trading on the NYSE American under the symbol "RGNT". Regentis' lead product, GelrinC®, is a cell-free, off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. As an innovative...

Read more

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

December 8, 2025 8:30 AM

In recent years, LIXTE (NASDAQ:LIXT) has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic angles for resistant cancers. The company built its early identity around that science, and for good reason. LB-100 remains one of the few agents capable of disrupting a key cellular checkpoint cancer relies on for survival. Late 2025 added a new dimension to that storyline. With the acquisition of...

Read more

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

December 8, 2025 8:10 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune‑modulatory antibodies for cancer immunotherapy, today announced the presentation of new data from the safety run-in portion of its ongoing trial evaluating BI-1206, an anti-FcγRIIB antibody, in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's...

Read more

Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia Presented at ASH

December 8, 2025 8:00 AM

Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation today announced further positive interim clinical results for Omisirge (Omidubicel-onlv), its advanced stem cell transplant therapy for Severe Aplastic Anemia (SAA). The data were presented by Dr. George Aue of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), at the American Society...

Read more

Faron Presents Updated BEXMAB Data at ASH 2025: Deep and Durable Responses in HR-MDS with Favorable Safety Profile

December 8, 2025 2:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the frontline HR MDS Key highlights: Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant improvement in a population with historically poor survival of only 5-6 months In...

Read more

BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025

December 7, 2025 8:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced the presentation of updated data from the ongoing Phase 2a monotherapy of BI-1808, a first-in-class anti-TNFR2 antibody, in cutaneous T-cell lymphoma (CTCL) in a poster at the 2025 American Society of Hematology (ASH) Annual...

Read more

Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease

December 6, 2025 8:00 AM

Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced encouraging real-world data on the use of motixafortide, a long-acting CXCR4 inhibitor licensed by Ayrmid under the brand name APHEXDA®, for mobilizing HSCs in patients with sickle cell disease undergoing gene therapy. The results were presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place from Dec 6-9 in Orlando FL....

Read more

FDA approves Omisirge(R) as First Approved Cell Therapy to Treat Severe Aplastic Anemia

December 5, 2025 4:47 PM

Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation announces that it has received U.S. Food and Drug Administration ("FDA") approval for Omisirge (Omidubicel-onlv) for the treatment of Severe Aplastic Anemia (SAA). This approval is based on the ongoing open-label, single-center study, led by Dr. Richard Childs of the National Heart, Lung, and Blood Institute (NHLBI) at the...

Read more

Revalia Bio Awarded Up To $26.7 Million ARPA-H Contract Award to Advance Drug Development with Human Data Trials

December 5, 2025 9:00 AM

Revalia Bio (Revalia), developer of the Human Data Trial platform, today announced that they are serving as the technical lead for an up to $26.7M contract that they were awarded under the Advanced Research Projects Agency for Health (ARPA-H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. The project, titled An Integrated Human Data Approach to Unlock the Future of In Silico Learning Models, supports...

Read more

Vicore to Present at the Oppenheimer Movers in Rare Disease Summit

December 5, 2025 2:15 AM

Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Oppenheimer Movers in Rare Disease Summit: Location: New York, USA Format: Fireside Chat and 1×1 meetings Presentation Date and Time: Thursday, December 11 at 9:00 AM ET Participant: Megan Richards, VP of IR, Communications, and Portfolio Strategy The company's...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

December 4, 2025 11:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) | Company announcement | December 04, 2025 at 18:00:00 EET TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd 1b. Please indicate if the issuer...

Read more